- $1.09bn
- $1.18bn
- $700.97m
- 74
- 54
- 78
- 78
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 7.79 | ||
| PEG Ratio (f) | 0.15 | ||
| EPS Growth (f) | 111.54% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.36 | ||
| Price to Tang. Book | 3.18 | ||
| Price to Free Cashflow | 6.82 | ||
| Price to Sales | 1.55 | ||
| EV to EBITDA | 259.71 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -6.06% | ||
| Return on Equity | -12.27% | ||
| Operating Margin | -10.97% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 429.65 | 541.53 | 666.82 | 674.98 | 700.97 | 739.06 | 818.74 | 10.73% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +1572.82 | -55.77 | -69.5 | +123.24 | -86.93 | +1810.11 | +19.14 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Pacira BioSciences, Inc. is the holding company for its subsidiary, Pacira Pharmaceuticals, Inc. The Company has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain, and iovera, a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201, a locally administered gene therapy with the potential to treat largely prevalent diseases like osteoarthritis.
Directors
- David Stack CHM (69)
- Charles Reinhart CFO (60)
- Max Reinhardt CEX (50)
- Kristen Williams CAD (47)
- Charles Laranjeira OTH (55)
- Dennis McLoughlin OTH (55)
- Roy Winston OTH (60)
- Paul Hastings LED (61)
- Christopher Christie DRC (58)
- Laura Brege IND (63)
- Mark Froimson IND (60)
- Yvonne Greenstreet IND (58)
- Mark Kronenfeld IND (66)
- John Longenecker IND (73)
- Gary Pace IND (73)
- Andreas Wicki IND (62)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- December 22nd, 2006
- Public Since
- February 3rd, 2011
- No. of Shareholders
- 9
- No. of Employees
- 790
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 46,304,667
- Address
- 2000 SIERRA POINT PARKWAY, SUITE 900, BRISBANE, 94005
- Web
- https://www.pacira.com/
- Phone
- +1 6502428052
- Contact
- Susan Mesco
- Auditors
- KPMG LLP
Upcoming Events for PCRX
Q3 2025 Pacira Biosciences Inc Earnings Release
Similar to PCRX
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Pacira Biosciences share price?
As of Today at 22:32 UTC, shares in Pacira Biosciences are trading at $23.48. This share price information is delayed by 15 minutes.
How has the Pacira Biosciences share price performed this year?
Shares in Pacira Biosciences last closed at $23.48 and the price had moved by -15.87% over the past 365 days. In terms of relative price strength the Pacira Biosciences share price has underperformed the S&P500 Index by -25.58% over the past year.
What are the analyst and broker recommendations for Pacira Biosciences?
The overall consensus recommendation for Pacira Biosciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Pacira Biosciences dividend yield?
Pacira Biosciences does not currently pay a dividend.
Does Pacira Biosciences pay a dividend?
Pacira Biosciences does not currently pay a dividend.
When does Pacira Biosciences next pay dividends?
Pacira Biosciences does not currently pay a dividend.
How do I buy Pacira Biosciences shares?
To buy shares in Pacira Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Pacira Biosciences?
As of the previous close price of $23.48, shares in Pacira Biosciences had a market capitalisation of $1.09bn.
Where are Pacira Biosciences shares listed?
Here are the trading details for Pacira Biosciences:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: PCRX
What kind of share is Pacira Biosciences?
Based on an overall assessment of its quality, value and momentum Pacira Biosciences is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Pacira Biosciences share price forecast for 2025?
The analyst consensus target price for shares in Pacira Biosciences is $41.50. That is 76.75% above the last closing price of $23.48.
Analysts covering Pacira Biosciences currently have a consensus Earnings Per Share (EPS) forecast of $2.75 for the next financial year.
Find out moreWhat is the trend in the Pacira Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pacira Biosciences. Over the past six months, its share price has outperformed the S&P500 Index by +14.34%.
As of the last closing price of $23.48, shares in Pacira Biosciences were trading +8.98% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Pacira Biosciences PE Ratio?
The Pacira Biosciences PE ratio based on its reported earnings over the past 12 months is 7.79. The shares last closed at $23.48.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Pacira Biosciences?
Pacira Biosciences' management team is headed by:
- David Stack - CHM
- Charles Reinhart - CFO
- Max Reinhardt - CEX
- Kristen Williams - CAD
- Charles Laranjeira - OTH
- Dennis McLoughlin - OTH
- Roy Winston - OTH
- Paul Hastings - LED
- Christopher Christie - DRC
- Laura Brege - IND
- Mark Froimson - IND
- Yvonne Greenstreet - IND
- Mark Kronenfeld - IND
- John Longenecker - IND
- Gary Pace - IND
- Andreas Wicki - IND